Ashkan Emadi, MD, PhD, discusses early efficacy signals with venetoclax plus pegcrisantaspase in relapsed/refractory AML.
Pegcrisantaspase Combo Offers Potential to Overcome Resistance to Prior BCL-2 Inhibitors in R/R AML
Ashkan Emadi, MD, PhD, discusses responses achieved with venetoclax plus PegC in patients with venetoclax-pretreated, relapsed/refractory AML.
The addition of pegcrisantaspase to venetoclax may overcome resistance to prior BCL-2 inhibitor–based regimens for patients with relapsed/refractory AML.
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5